J&J, Pfizer, Novartis are the in-demand pharmas among job-seekers, LinkedIn says

Tracy Staton Hiring and keeping good employees is as much of a challenge in the drug business as it is anywhere else. So, it's always nice to know that would-be job seekers think ...

Orphan drug prices on non-orphan meds? Gilead, this means you, PBM says

Tracy Staton Anyone following the hepatitis C drug market knows that Express Scripts CMO Steve Miller has a strong point of view. FiercePharma News

After strong Q3, no $55B deals in AbbVie’s future, CEO says. But a smaller one? Maybe

Carly Helfand No Shire? No problem for AbbVie. At least, for now. FiercePharma News

Alcobra says its ADHD drug works–as long as you don’t compare it to placebo

Damian Garde Alcobra is touting the benefits of its in-development ADHD treatment, saying the drug provided a statistically significant benefit over placebo–but only after the ...

Lilly says with new data, it will seek another approval for Cyramza next year

Eric Palmer Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to ...

Prefer a Swiss tax rate? Basilea chief says he’s ready to parley

John Carroll Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick ...

China sets trial date for GSK-tied investigators, says it will be ‘open’

Carly Helfand China will try two private investigators tied to GlaxoSmithKline's operations there in just over a week on charges of illegally purchasing personal information about ...

Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong

Eric Palmer Gilead Sciences got to the market first with an interferon-free oral hepatitis C fighter, a category projected to hit $ 20 billion in sales by 2020. Its Sovaldi has been ...

France health minister says EU will fight price of Gilead’s Sovaldi

Eric Palmer Resistance to the price that Gilead Sciences has put on Sovaldi, a drug that will cure millions of hepatitis C, is reaching a fever pitch. Now 14 European countries are ...

Not for sale, says new Actavis CEO. We’re buying instead

Tracy Staton After serving as Bausch & Lomb's chief exec for just 5 months, incoming Actavis CEO Brent Saunders wants to keep his new job for awhile. So forget selling the company, ...

Germany says it is unclear whether Gilead’s Sovaldi prevents liver cancer

Eric Palmer Gilead Sciences has argued that its hep C blockbuster Sovaldi will save healthcare payers money by preventing transplants for patients who develop cancer. But now the U.S. ...

Teva could jump into pharma’s deal frenzy, CEO says

Carly Helfand A few months ago, Teva CFO Eyal Desheh told the J.P. Morgan Healthcare Conference that armed with a new incoming CEO and a reasonable debt level, the Israeli company was ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS